Series Sponsors:





With Support From:

• When: February 12, 8:00am - 10:00am
  
• Where: Cooley Godward Kronish LLP, Palo Alto, CA Directions.
  
• Attire: Business Attire Suggested

"When is it time to sell?" Whether you are the founder of a medical device company with a product in development or the executive of a company with products in the market, the issue of when and if to sell is often the most pivotal question faced by the entrepreneurs and the executives, board members and stockholders of any company.

As the overall costs associated with product development, clinical studies, regulatory approval process, and commercialization have steadily increased in the past several years, the capital and funding requirements for medical device companies have also increased. Entrepreneurs and existing investors are often faced with the issue of whether they should seek additional capital and incur the inherent dilution and other issues associated with a new round of funding or to seek the outright sale of the company. In recent years, the IPO market has been used by some medical device companies as a means to raise additional capital while ultimately providing some liquidity to existing investors. In addition, many companies have utilized strategic partnerships and alliances as a means of defraying the costs, and potentially accelerating the timelines, associated with product development and commercialization. Some companies have pursued a 'dual-path' strategy of pursuing an IPO while at the same time engaging in strategic discussions in an effort to potentially maximize the returns to stockholders.

The panel of experts will explore the key issues and considerations in whether or not to sell the company, and share their experiences in an open round-table format. The following will be among the topics explored: What are the best and worse reasons for considering the sale of the company? What successes & failures are we seeing? What are some industry trends affecting the medical device M&A landscape? What are some of the key consideration from the founders' or management's standpoint? What are the alternatives to an outright sale of the company?

Panel Moderator:

Frank F. Rahmani
Partner, Cooley Godward Kronish LLP

Panel Speakers:

David Clapper
Chief Executive Officer, SurgRx; former CEO of Novacept (sold to Cytyc)

Jeff Gold
Venture Partner, Longitude Capital; former CEO of CryoVascular Systems (sold to Boston Scientific Corporation)

Jay Watkins
Managing Director, De Novo Ventures; Co-founder of Origin Medsystems (sold to Eli Lilly & Company)

Registrations:
If you are an employee of a Partner or Sponsor company, please contact
Program Director, Misha Tsirulnikov to obtain your complimentary registration.

On-line reservations: CLICK HERE
Reservations by mail or fax: CLICK HERE

Early Bird Registration through February 11, 2008:
$10.00 BayBio Members
$25.00 Non-Members

On-Site Registration, February 12, 2008:
$20.00 BayBio Members
$40.00 Non-Members

• Pre-registered attendees will receive an immediate receipt/confirmation after submission.
  Please print this receipt/confirmation and bring it with you to receive your conference credentials.
  Photo ID (driver's license or passport) will be required at check-in.
• All sales are final - BayBio offers no refunds.

Please mail your event-related questions to: events@baybio.org or you can contact us via phone: 650-871-7101.
Is your company a member? Click here to check.
See how your company can save money by becoming a BayBio member!